Overview

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Status:
Enrolling by invitation

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This will be an open-label, 3-sequence, 3-period crossover study in healthy adult participants to assess the relative bioavailability of ACH-0145228 when administered as an immediate release tablet versus powder-in-capsule.

Phase:

Phase 1

Details

Lead Sponsor:

Alexion Pharmaceuticals

Collaborator:

Celerion